Mrs Sharon Hodgson
MP for Washington and Gateshead South · Labour · United Kingdom
“T5. I visited Newcastle Crown court before the summer recess, where I learned that the backlog of cases had reached an unprecedented high. As we have heard, measures such as the blitz courts in Teesside, which were mentioned earlier, and specialist sexual offences and domestic abuse courts can help with this backlog.”
“Thank you, Madam Deputy Speaker; I will be very brief. Next Thursday is World Patient Safety Day. As the landmark Cumberlege review confirmed, patients—particularly women—have had their concerns dismissed and denied for far too long.”
“It would ensure that that support is actually accountable to Parliament, with an annual mandatory report highlighting the services that have been provided and the outcomes that they have achieved.”
“Getting this right matters because when we do not, children suffer. Research shows that 10% to 25% of children experience disorganised attachment with their main caregiver, putting them at greater risk of poor social, emotional and educational outcomes.”
“Parents are expected to know just by instinct how to fulfil this role, and that is where we have gone wrong. If we want a healthy and happy society, we need our children to be thriving and therefore our parents and carers to be supported from the very start.”
“If we instead focus on building conditions that allow parents, carers and babies to thrive, we allow children to thrive from the beginning, rather than waiting to intervene when they struggle later down the line. Babies should not be an afterthought.”
The complete record
Every one of 602 lines we hold for Mrs Sharon Hodgson, in date order, each linked to its source. Free to read, in full, without an account. Page 3 of 13.
“Absolutely. Digital services will complement and not replace the face-to-face care, so we are developing the NHS app and expanding online consultations for those for whom it will be helpful. There will be digital triage and remote monitoring, allowing patients in rural areas to access more NHS services, but I take on board the hon. Lady’s point about ensuring that we do not exclude people. It is important to recognise that decisions about individual services are made locally by NHS organisations, which are responsible for assessing the needs of their populations and planning services accordingly. As strategic commissioners, ICBs work closely with health and wellbeing boards, local authorities and other partners to identify the most impactful outcomes for their population.”
“Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) for her tireless work as the chair of the all-party group and for her committed campaigning on behalf of brain cancer patients in memory of her sister Margaret McDonagh, who so many of us knew so well and remember so fondly.”
“It is a pleasure to serve under your chairmanship today, Mrs Barker. I thank my hon. Friend the Member for Colne Valley (Paul Davies) for introducing the petition on behalf of the many people who signed it and secured the debate today. It has been so well attended, as we can see from the number of Members here and the fact that the Gallery is full, which really shows its importance. Earlier this month, I was honoured to join a meeting of the all-party parliamentary group on brain tumours, which was also very well attended, and to hear the personal stories and lived experience shared by those affected by brain cancer. I thank my hon.”
“Friend the Member for West Lancashire (Ashley Dalton), made sure that the national cancer plan would be the first plan in history to have a chapter dedicated to rare cancers. There are not enough treatment options available for people with brain cancer. I have spoken to so many patients and campaigners who are searching for that glimmer of hope on clinical trials. This desperate search takes a real toll on them, not to mention their families and carers. We will prioritise their access to specialist treatment and multidisciplinary teams, and we want to ensure that all patients with rare cancer can benefit from the best care available. We will work with charities to make sure that patients are getting the right information to manage their cancer care. We are rolling out Jess’s rule and tracking cancer diagnosed in emergency settings.”
“Absolutely. I cannot think of a worthier cause than turning brain cancer from terminal to treatable. That is something that we can absolutely all get behind. I am especially grateful to Brain Cancer Justice, which led the campaign for the petition and this very well-attended debate, as well as Brain Tumour Research and the Brain Tumour Charity. They all do fantastic work advocating for people diagnosed with a brain tumour and their loved ones. Since this Government came into office, over 232,000 more people got a cancer diagnosis or an all-clear on time, about 42,000 more patients started treatment on time, and rates of early diagnosis are hitting record highs. A lot has been done, but there is a lot more to do, especially on rare and less common cancers. That is why my predecessor, my hon.”
“I am certainly happy to look at the model in the US around the right to try. I also want to update the House that we are appointing a national clinical lead for rare cancers, who will sit on the national cancer board. The benchmark is to improve outcomes and five-year survival rates for 14 less common cancers, including brain cancer. I know that Members will all hold us to account on that score.”
“I thank my hon. Friend for raising the late, great Tessa Jowell in this debate. I had the privilege of being the shadow Health Minister and speaking in one of the debates we had in the House, and her legacy does live on. I must move on, because I want to talk about brain cancer research.”
“It is also my job to be their voice in Government, and I take that role very seriously. For the last 20 years, I have sat where other Members are or where the shadow Minister is, so I completely understand where everyone is coming from. I think I am going to run out of time, but 35 Back Benchers have spoken—”
“I have also asked the Department and NHS England to work with professional bodies, including the Royal College of Pathologists, to review tissue retention guidance and consent processes, which is what we discussed. We are looking at ways to support trusts to expand freezer capacity, and I will be happy to update colleagues in the autumn. My hon. Friend the Member for Hastings and Rye (Helena Dollimore) and my right hon. Friend the Member for Hayes and Harlington (John McDonnell) asked me about workforce. We will be publishing the 10-year workforce plan imminently; it will set out action to create a workforce ready to deliver the transformed services set out in the 10-year health plan. I want to end by saying that I do not see it as my job just to represent the Government to patients and campaigners.”
“We have announced a clinical trials accelerator, Be Part of Research, which allows users to search for relevant studies and register their interest. I turn to brain tissue freezing and to the specific points raised by my hon. Friend the Member for Caerphilly (Chris Evans) and so many others. Earlier this month, I met him and other colleagues, as well as Ellie James, the campaigner for Owain’s law. Can I just say how moved I was? My hon. Friend knows that no one can fail to be moved by Ellie’s story. She spoke for many people, not just in Wales but across the United Kingdom, and I have asked the NHS to take action. NHS England has completed a gap analysis of the need for freezer capacity, as my hon. Friend mentioned, and is looking at how to support services to provide an equitable expansion of that capacity.”
“That appointment is under way, and that person, once appointed, will make sure that we are delivering research for patients. Implementing the Act will also make it easier for researchers to connect with patients living with rare cancers, including brain tumours, and streamline recruitment into clinical trials. Our 10-year health plan will make the UK a global leader in clinical research, because we want every patient in the country to have the chance to sign up to a clinical trial should they wish to do so. The hon. Members for Kingswinford and South Staffordshire (Mike Wood) and for Esher and Walton (Monica Harding) and my hon. Friend the Member for Mansfield (Steve Yemm) all asked me about clinical trials.”
“We will continue to fund research that is recommended by our funding committees and independent peer reviewers. That includes more than £25 million for the NIHR brain tumour research consortium, which brings together 48 organisations across the UK in a national, co-ordinated effort to help deliver better research faster. We are also partnering with Cancer Research UK, providing almost £3 million to co-fund the brain tumour centres of excellence; this collaboration will accelerate the delivery of innovative treatments to patients. We will continue to build on our investments and fund high-quality brain cancer research. As we reaffirmed in the national cancer plan, the Government will implement the Rare Cancers Act in full, starting with the appointment of an NIHR national specialty lead for rare cancers this summer.”
“I will come back to the hon. Gentleman’s point. I really do have to get through some things and respond to the number of people who spoke about brain cancer research, because nearly all hon. Members mentioned that. Through the National Institute for Health and Care Research, we have directly invested more than £32 million since the general election. My hon. Friend the Member for Colne Valley and so many other colleagues mentioned the £40 million commitment for brain cancer research in 2018 and the fact that it had not all been spent. Prior to the general election in 2024, that was the case, but I can confirm that since the general election, the spend from NIHR programmes alone has now been in excess of £40 million since 2018. That £40 million is not a funding ceiling.”
“I have spent the best part of 20 to 30 years—21 years of them in this place—fighting alongside campaigners on this issue, along with many others. Now I am in government, they are all at the forefront of my mind. When it comes to cancer, colleagues are pushing at an open door with me. I will never forget my roots as chair of the all-party group and as a daughter-in-law of someone lost to secondary breast cancer at far too young an age. The hon. Member for Wokingham has a very personal connection to this campaign, and the all-party group could not be in better hands with him as its chair. Let me end by thanking all hon. Members for keeping me on my toes. If I have not responded to any points made by the shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson), or by others, I commit to doing so in writing.”
“Friend the Member for West Lancashire spoke about the cancer clinical trials accelerator. I assure her that the Department, NHS England and the NIHR are working hard to develop and set up the accelerator to the timeline set out in the national cancer plan. The hon. Member for Strangford (Jim Shannon) asked me once again about clinical trials at Queen’s University Belfast and what discussions Ministers had had with Northern Ireland Ministers. I commit to writing to him with further information on that matter. His plea at the end for more screening, more funding and more saving of lives did not fall on deaf ears for anyone in this Chamber, I am sure. It has been a privilege to respond on behalf of the Government today.”
“Members for Horsham (John Milne) and for North East Fife (Wendy Chamberlain) spoke about lobular breast cancer and the Lobular Moon Shot Project. I assure the House that Government funders are committed to continuing to work with researchers to support the development of fundable research proposals to drive a stronger understanding of the biology behind lobular breast cancer, as well as to develop effective treatments. In April, Lord Vallance and I, alongside the National Institute for Health and Medical Research Council representatives, met representatives of the Lobular Moon Shot Project. It was a very interesting meeting, I must say. Lord Vallance will also host a scientific roundtable on lobular breast cancer this month—one of the commitments we made at that meeting. My hon.”
“That is why we are also setting up a new health data research service by the end of this year. It will provide a secure single access point for researchers, including data relevant to cancer diagnosis, care and outcomes. That means that wherever they live in our country, whether Washington, Wokingham or Durham, scientists will be sitting on a treasure trove of data for their research. Our life sciences sector plan commits us to working with industry to accelerate growth in spending on innovative medicines. Just last year, a cutting edge oral targeted cancer therapy that helps to slow or stop cell growth was approved for treating advanced breast cancer on the NHS in England. I turn to some specific points made by hon. Members. The hon.”
“It can then be linked to give us a good idea on numbers until we can get an even clearer picture through trust reporting. We are already off to a good start because data was already starting to improve under this Government, even before the national cancer plan was published. Consecutive audits of metastatic breast cancer by the National Cancer Audit Collaborating Centre, or NATCAN, cover a greater number of people living with metastatic breast cancer. Data coverage of metastatic breast cancer is already improving, and the NDRS will also publish a baseline assessment of incidence and prevalence and the total number of people living with metastatic breast cancer by the end of this year. It will be the best assessment we have ever had. Cancer patients deserve to have the finest minds in the country harnessing the data to make a difference.”
“I can update the House today that since the publication of the national cancer plan, the NDRS has made the collection and reporting of secondary breast cancer a key priority. It is co-ordinating with all partners, charities, teams of experts and trusts to properly collect data on secondary breast cancers at source. It is helping trusts to improve the way they collect data for things like disease progression, recurrence and metastatic spread. In the meantime, the NDRS is teaming up with researchers at the University of Oxford to develop a new algorithm. This infers the numbers of metastatic disease by combining multiple routine datasets. In plain English, what it means is this: trusts routinely report all sorts of data to NHS England—imaging, chemo, radiotherapy. All that data comes into NHSE from different places across the country.”
“In the words of Jo Taylor, the late founder of METUPUK, “We are only counted when we are dead”, and that is just unacceptable. As part of Jo’s legacy, we now have a specific commitment in our national cancer plan to begin collecting data for recurrent cancers, starting with metastatic breast cancer. I pay tribute once again to my hon. Friend the Member for West Lancashire for personally making sure that that commitment was there. Now that I have picked up her baton, as I said, I am determined to make sure we can make good on that promise. The national disease registration service is working with NHS trusts to improve their reporting of non-primary cancers in the cancer outcomes and services dataset.”
“The more data we collect, the more we can empower patients to make informed choices about their care, but it is not just about giving patients a clearer picture, important though that is. The Government made data one of the five big bets of our 10-year health plan—I think that is the right terminology—because the NHS is a data superpower. Just as coal was the fuel of the first industrial revolution, data will power the life sciences revolution, and we can use datasets to help scientists make further breakthroughs in cancer research. Better data is also important for researchers to understand the number of cohorts they have to work with. It is important for NHS commissioners, who will have a clearer idea of patient demand. We cannot improve something that we cannot measure.”
“How she was able to do that—there is a huge workload in this brief—on top of her treatment, while at the same time driving progress on the 10-year health plan, the HIV action plan and the men’s health plan, is testament to how focused, tough and brilliant she is. I am not afraid to admit that following in her footsteps is a challenge. I am thrilled that she is with us today, and we all witnessed her brilliance at first hand in her speech. I want to come to the substance of the issues that hon. Members have raised. If I run out of time, or if there is anything that I miss, I and my officials will write to hon. Members, so they should not think that I have just ignored what they said. It will be responded to in due course. I want to start with data.”
“Members who have shared their stories and those of constituents and campaigners, and for all those I have met since I was first elected to Parliament. This has been a very moving and informative debate, with so many excellent speeches from hon. Members. I particularly commend my predecessor as Public Health and Prevention Minister, my hon. Friend the Member for West Lancashire, for her fantastic work on the national cancer plan. It was all the better for being led by someone not just with lived experience, but who was actually in the middle of her cancer treatment at the same time.”
“Her secondary breast cancer—like that of my hon. Friend the Member for West Lancashire (Ashley Dalton)—was diagnosed 10 years after her primary breast cancer. That struck me and brought it back to mind. I was thinking how glad and happy I am that the treatment now is so much better than it was 30 years ago, and that my hon. Friend is very much still alive and kicking—and in great voice, as we have all heard today. Losing my mother-in-law at such a young age spurred me on, as a new MP in 2005, to join the all-party parliamentary group on breast cancer. I went on to be an officer and then chair for a number of years. Now that I am in government, I feel an immense responsibility resting on my shoulders. I want to do the right thing not just in memory of my mother-in-law, but for all hon.”
“It is a pleasure to serve under your chairmanship, Mr Betts. I am very grateful to my hon. Friend the Member for City of Durham (Mary Kelly Foy) and the hon. Member for Wokingham (Clive Jones) for raising this important matter and securing the debate. They both spoke about their own breast cancer journeys very powerfully, and I thank them for sharing their personal experiences with us. It is also personal to me, having gone through it not myself, but through my mother-in-law, who we lost to breast cancer almost 30 years ago. She was just 62, which is not much older than I am now. Thirty years ago, that age seemed a long way off, but now that I am 60, it does not seem very old at all. My father-in-law, who is in his nineties, is still with us, which made me realise how much life this terrible disease robbed her of.”
“We therefore consider it appropriate to proceed now, following the Food Standards Agency’s safety assessment, to allow the substance to be used in Great Britain as soon as possible. In summary, the regulations fulfil our requirements to update food supplement regulations where new substances have been authorised for use in food supplements and we continue to uphold high standards of safety and quality for consumers. I commend the draft regulations to the Committee.”
“During this period, only the applicant may use and sell magnesium L-threonate monohydrate as a form of magnesium, unless another business obtains authorisation based on its own data or with the applicant’s permission. In the longer term, other businesses will benefit from the authorisation of this substance, supporting choice and product innovation while maintaining robust safety standards. Food supplement legislation is in scope of the UK-EU sanitary and phytosanitary—or SPS—agreement, which will involve alignment with EU legislation in this area. In this case, this substance has already been authorised for use in the EU, so we expect no change in practice for businesses when alignment takes place.”
“The criteria specified in this instrument reflect the scientific specification assessed by the Food Standards Agency and ensure that, where this substance is used, it is manufactured and marketed to a consistent and safe standard. Food law is a devolved matter and this instrument applies in England only. Wales and Scotland have made equivalent amendments to their food supplement regulations, and Northern Ireland applies the existing European Union equivalent regulations, as required by the Windsor framework. It is important to emphasise that this measure is enabling, not mandatory; it does not require any business to use this ingredient or to change their products. The use of this new optional substance initially affects only the applicant who requested this authorisation, who benefits first from a five-year exclusive use period.”
“However, different chemical forms of that mineral must also be specifically listed before they can be used. A related statutory instrument, the Nutrition (Amendment etc.) (EU Exit) (Amendment) Regulations 2026, already laid under the negative procedure, adds this substance to the list of permitted forms of magnesium. However, for food supplements containing this substance to be lawfully sold, purity criteria must also be established, and an SI following the affirmative procedure is required to set the purity criteria for this substance in legislation. That is the sole purpose of the regulations before this Committee today.”
“This statutory instrument is a routine and technical measure that ensures that food supplement regulations continue to operate effectively following the authorisation of novel substances for use in food supplements. The regulatory approach taken here is well established: where new substances are authorised, it is necessary to update the relevant legislation so that they can be used in practice and to ensure that clear and enforceable quality standards are in place. Hon. Members will be aware that, under our existing legal framework, vitamins and minerals may be used in food supplements only if they are both listed in legislation and meet appropriate safety and quality standards. Magnesium itself is already a permitted mineral listed in legislation.”
“I beg to move, That the Committee has considered the draft Food Supplements Purity Criteria (Magnesium L-threonate monohydrate) (England) Regulations 2026. It is a pleasure to serve under your chairmanship this afternoon, Sir Edward. Magnesium L-threonate monohydrate—just to say it again—has recently been authorised as a novel food following a public consultation and safety assessment by the Food Standards Agency, which concluded that it is safe under the proposed conditions of use. The instrument sets the purity criteria—that is, the required safety and quality standards—for this form of the mineral magnesium to permit its use and sale in food supplements in England.”
“As I said in my opening remarks, this instrument is a routine technical measure to update food supplement regulations following the authorisation of magnesium L-threonate monohydrate as a novel ingredient to ensure the appropriate purity criteria are in place so that it can be used and sold lawfully in food supplements in England. It does not place new burdens on businesses, but ensures that any use of the substance meets clear and consistent safety and quality standards, which I think is what the hon. Lady was driving at in her questions. I invite the Committee to support these draft regulations, and I commend them to the Committee today. Question put and agreed to.”
“I thank all Members for coming along and supporting the important measures before us today. I thank the hon. Member for Sleaford and North Hykeham for her questions. I have made a note of them, and I am sure my official has as well. I have a huge binder full of information here, in which I could attempt to find the right answer for the hon. Lady—but, if she does not mind, I will commit to write to her on those very important points. I agree with her that it does sound like a possible wonder supplement; perhaps we should all rush out and buy some, especially if it helps with sleep. I know we could all do with a bit more of that. Specifically, the dosing plan, how often the purity will be tested and whether it does what it says on the tin are very important questions, so I will commit to write to her.”
“Health visitors play a vital role in supporting babies, children and families. Under the previous Government, the number of health visitors fell significantly, which is why this Government have taken action. The upcoming professional strategy for nursing and midwifery will set out a bold direction of travel to strengthen health visiting across England. We have already made improvements with all post-birth health and development reviews now completed for over 80% of children nationally, which is the highest level since recording began.”
“I thank my hon. Friend for being so brave and willing to share his and his wife’s birth trauma, and to talk about the lack of support afterwards, not just with Baroness Amos and her review but with the House today. I know personally how hard it is to do that, but I also know the huge difference it can make to Government policy. I am happy to commit to him today that the Government will absolutely look closely at all the findings in Baroness Amos’s review, and work with the national maternity taskforce to translate the recommendations into action. I am also pleased to confirm that we have recently updated our national health visiting guidance to include a high impact area on family mental health, with a clear focus on supporting both mothers and fathers.”
“Yes, I will. We are busy working on the 10-year workforce plan. The training of all the NHS workforce, including health visitors, is a big part of that. In my new position as public health and prevention Minister, I am particularly interested in the work of health visitors, especially with regard to supporting rates of breastfeeding. The hon. Gentleman will be aware that the results of the breastfeeding survey were released last week and they showed substantial improvement.”
“I thank my hon. Friend for raising that very important matter. My sympathy is with the Lake family, and I commend them for their advocacy on this issue. I am acutely aware of the matter, having met the hon. Member for Upper Bann (Carla Lockhart) and her constituents about this issue last week, in a very moving meeting. I assure my hon. Friend that the Department is working with partners to see whether it is possible to set up a multi-condition evaluation, so that not only MLD but other rare conditions can be assessed alongside the existing screening programmes.”
“People with Parkinson’s disease should receive support tailored to their individual needs, as symptoms and progression vary. The NHS provides specialist multidisciplinary NHS care informed by guidance from the National Institute for Health and Care Excellence and improvement programmes such as Getting It Right First Time. People with Parkinson’s will benefit from our wider work to strengthen community services, reduce waiting times and improve co-ordinated, person-centred care closer to home. I assure my hon. Friend that the Department will continue to meet regularly with Parkinson’s UK to ensure that their voices are heard.”
“I am aware of my hon. Friend’s significant work in this policy area, and she is absolutely right about the huge potential of TAVIs. Rising national TAVI activity and improved “Getting it right first time” pathways are part of our approach to reduce health inequalities and support more timely, equitable care. Through that work, the Government are committed to strengthening consistency in the diagnosis and treatment of heart valve disease, building on progress already made.”
“I commend my hon. Friend for her great work and that of the APPG in highlighting the importance of endometriosis and the impact it can have. We would be delighted to continue our close engagement with her and the APPG on this topic. We will consider the APPG’s findings carefully when they are published, as part of our ongoing work to improve diagnosis, treatment and support for women with endometriosis.”
“We know that the earliest stages of a child’s life are critical for their development, and the Government are committed to supporting families to give babies the best start in life. We are investing over £900 million in the Best Start family hubs and healthy babies programme to create an integrated, accessible system of support for families. I particularly look forward to considering the merits of the private Member’s Bill that the right hon. Gentleman will present to Parliament, and I do indeed look forward to meeting him to discuss that further.”
“The Royal College of General Practitioners also has an e-learning module for GPs on the diagnosis and management of osteoporosis, developed in collaboration with the Royal Osteoporosis Society—I am sure that my hon. Friend the Member for Dudley was telling me that she was the chair or the president of the society.”
“The neighbourhood health service, supported by the neighbourhood health framework that we published last month, will ensure that people can better access care that is joined up, personalised and designed to proactively meet their needs. Initiatives such as Diagnosis Connect will also directly refer patients to specialist charities at the point of diagnosis for personalised advice, information, guidance and support. Resources are already in place to help support healthcare professionals in the early diagnosis of osteoporosis, such as the National Institute for Health and Care Excellence clinical knowledge summary on osteoporosis and the prevention of fragility fractures.”
“We hear too often—as we have today—of patients experiencing painful fractures that could have been prevented, of patients living in fear of having further fractures, and the impact that that has on their independence, wellbeing and quality of life. We recognise the importance of bone health and the benefits that early identification of people at risk of osteoporosis and the prevention of fragility fractures can bring. The 10-year health plan sets out a vision for a health and care system that delivers more personalised, integrated and proactive care for people with long-term and complex conditions, including osteoporosis and other musculoskeletal conditions. More tests and scans delivered in the community, better joined-up working between services and greater use of technology will all support people in the management of osteoporosis.”
“Friend’s APPG does important work in raising awareness of osteoporosis, advocating for improvements to the care that patients receive, and promoting behavioural and system changes that are designed to strengthen bones and prevent osteoporosis. Osteoporosis is estimated to affect more than 3 million people in the UK, and each year over half a million patients present to hospitals with fragility fractures. It is important that we acknowledge the significant impact that osteoporosis can have on individuals and their loved ones. It can seriously impact every aspect of a person’s life, as we have heard, and has a significant impact on the NHS and the wider economy.”
“It is a pleasure to serve under your chairship, Ms Lewell. I thank my hon. Friend the Member for Dudley (Sonia Kumar) for securing this important debate. She continues to work as a physiotherapist alongside her role as a serving MP, so she brings a wealth of valuable professional clinical experience and knowledge to this debate. I would be very happy to meet her afterwards to discuss her three recommendations. I also thank her for her as the chair of the APPG on osteoporosis and bone health. As an MP for 21 years, I have done lots of work on APPGs, and I am—as I know our Chair today is—a big supporter of all APPGs. The work they do is so important and can really make changes to policy. My hon.”
“I recognise that we must go further, but I reaffirm the Government’s commitment to support the millions of people in the UK who are living with osteoporosis to ensure that they get the support they need, including improved diagnosis and management. I look forward to meeting with my hon. Friend. Question put and agreed to.”
“By aligning with employment support at local level, this project will seek to improve both health and work outcomes for people with MSK conditions, such as osteoporosis, while prioritising those experiencing unmet MSK health needs and living in areas of deprivation, with the aim of addressing health inequalities. I thank my hon. Friend the Member for Dudley again for securing this important debate and all the work she does in this area, and I thank other hon. Members for being present and for raising insightful points during the debate. I hope hon. Members are reassured by some of the measures I have outlined.”
“We are joining up health and employment support around the individual through the WorkWell programme, MSK hubs, the MSK community delivery programme, and the individual placement and support in primary care initiative. Measures also include support from work coaches and disability employment advisers in jobcentres, and access to work grants. We also recognise the benefits of physical activity in improving bone strength and reducing the risk of fractures. We are exploring ways to expand access to MSK physical activity hubs in the community, enabling the delivery of evidence-based physical activity interventions for individuals with MSK conditions.”
“I was so glad to hear the intervention from my hon. Friend the Member for North Warwickshire and Bedworth (Rachel Taylor), who said she had taken some of those new medications. They help to strengthen bones and prevent bone loss, reducing the risk of fractures. The renewed women’s health strategy published last week sets out our ambition to support healthy ageing, maintain independence and improve quality of life for women, while also reducing avoidable pressure on hospital services. Turning to work and health, the Government are committed to supporting disabled people and those with health conditions, including MSK conditions such as osteoporosis, with their employment journey. We therefore have a range of specialist initiatives to support individuals to stay in work and get back to work.”